Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 5/20 | 0.47 |
| ▸ | BACE1 | P56817 | 3/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11043050 | 1.00 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSL | |
| SCHEMBL10535982 | 1.00 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSL | |
| SCHEMBL11137675 | 1.00 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSL | |
| SCHEMBL5411977 | 1.00 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSL | |
| SCHEMBL7828875 | 1.00 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSL | |
| SCHEMBL10537924 | 0.87 | REN (0.57) | CA1CA2CA7CYP2D6REN | |
| SCHEMBL10977303 | 0.87 | CA1 (0.53) | CA1CA2CA7CYP2D6REN | |
| SCHEMBL764842 | 0.87 | REN (0.57) | CA1CA2CA7CYP2D6REN | |
| SCHEMBL8270788 | 0.86 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSL | |
| SCHEMBL10573647 | 0.85 | CA1 (0.51) | CA1CA2CA7CYP2D6REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0309297-B1 | Therapeutic peptides | UNIV TULANE (US) | 1994-11-09 | — | — | EP | claimed |
| EP-0309297-A2 | Therapeutic peptides | The Administrators of The Tulane Educational Fund (US) | 1989-03-29 | — | — | EP | claimed |
| US-4397786-A | Method of preparing statine and derivatives | MERCK & CO., INC. (US) | 1983-08-09 | — | — | US | claimed |
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
| EP-4029501-A1 | COMBINATION OF POLYAROMATIC UREA DERIVATIVES AND GLUCOCORTICOID OR HDAC INHIBITOR FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH MUSCLE CELLS AND/OR SATELLITE CELLS | Anagenesis Biotechnologies (FR) | 2022-07-20 | — | — | EP | disclosed |
| EP-3999057-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES SAS (FR) | 2022-05-25 | — | — | EP | disclosed |
| CN-114144410-A | Polyarylurea derivatives and their use in the treatment of muscular diseases | 阿纳格纳斯生物技术股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| WO-2016197190-A1 | STRUCTURE OF PLASMEPSIN V IN COMPLEX WITH AN INHIBITOR AND USES THEREOF | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2016-12-15 | — | — | WO | disclosed |
| US-8101661-B2 | Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same | KEMPHARM, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110213034-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2011-09-01 | — | — | US | disclosed |
| US-20100292337-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2010-11-18 | — | — | US | disclosed |
| EP-0206807-A2 | Novel amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1986-12-30 | — | — | EP | disclosed |
| EP-0200406-A2 | Novel amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1986-11-05 | — | — | EP | disclosed |
| EP-0190891-A2 | Novel amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1986-08-13 | — | — | EP | disclosed |
| EP-0186977-A2 | Renin-inhibitory dipeptides, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1986-07-09 | — | — | EP | disclosed |
| US-4548926-A | RENIN INHIBITOR | SANKYO COMPANY LIMITED (JP) | 1985-10-22 | — | — | US | disclosed |
| EP-0155809-A2 | Renin inhibitors containing statine or derivatives thereof | PFIZER INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0152255-A2 | New renin-inhibitory peptides and their use | SANKYO COMPANY LIMITED (JP) | 1985-08-21 | — | — | EP | disclosed |
| EP-0128762-A2 | New hypotensive peptides, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1984-12-19 | — | — | EP | disclosed |
| US-4397786-A | Method of preparing statine and derivatives | MERCK & CO., INC. (US) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292337-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A2, SLC6A3, SLC18A2 | CA1 2576/4885CA2 3812/4885CA7 3152/4885 |
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | CKMT1A; CKMT1B, TNNC1, UBQLN2 | CA1 4765/4885CA2 4350/4885CA7 3754/4885 |
| US-20110213034-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A3, SLC6A2, SLC6A15 | CA1 1877/4885CA2 3250/4885CA7 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.